key: cord-0834095-hos4nu11
authors: Hage, Chadi A.; Klesney‐Tait, Julia; Wille, Keith; Arcasoy, Selim; Yung, Gordon; Hertz, Marshall; Chan, Kevin M.; Morrell, Matt; Goldberg, Hilary; Vedantham, Suresh; Derfler, Mary Clare; Commean, Paul; Berman, Keith; Spitznagel, Ed; Atkinson, Jeff; Despotis, George
title: Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
date: 2021-05-05
journal: Transfus Med
DOI: 10.1111/tme.12779
sha: b116183d8931dd2c560253fe3dc8caacde007daa
doc_id: 834095
cord_uid: hos4nu11

BACKGROUND: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV(1) in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed. STUDY DESIGN AND METHODS: Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV(1) decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint. RESULTS: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non‐random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV(1) decline that were reduced by 93% in evaluable ECP‐treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV(1) decline were observed in the non‐survivors (−212 ± 177 ml/month) when compared to the survivors (−95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment. CONCLUSIONS: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP.

Results: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non-random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV 1 decline that were reduced by 93% in evaluable ECP-treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV 1 decline were observed in the non-survivors (À212 ± 177 ml/month) when compared to the survivors (À95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment.

Conclusions: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP. 1 with an annual incidence that exceeds 7%-8% in the first 10 years after transplantation. 2 BOS is an irreversible fibroproliferative immune process that results in progressive narrowing of bronchial lumens, ultimately resulting in complete airway occlusion. 3 Despite current clinical use of one or more on or off-label treatment options, no immunosuppressive regimen has been shown to consistently prevent BOS. 4, 5 Extracorporeal photopheresis (ECP), a pheresis-based therapeutic immunomodulatory intervention, was approved by the FDA in 1987 for the management of cutaneous T-cell lymphoma. 6 ECP is additionally covered by Medicare for two off-label uses: management of GVHD after bone marrow transplantation 7, 8 and for cellular rejection of orthotopic heart transplants. 9 Since the early 1990s, ECP has also been used on an off-label basis for treatment of BOS refractory to the currently available armamentarium of immunosuppressive agents in lung transplant recipients. [10] [11] [12] [13] [14] [15] [16] Three retrospective analyses have demonstrated a reduction in the rate of decline of lung function in $80% of lung transplant recipients with BOS. [14] [15] [16] Based on these findings, we submitted a formal request to the US Centres for Medicare and Medicaid (CMS) to revise its ECP National Coverage Determination (NCD) to cover this treatment for patients with refractory BOS.

Pursuant to concerns raised by CMS regarding the study design for a prospective trial, we pursued a follow-up analysis of our previously published 60-patient database 16 to address these issues. In this re-analysis, FEV 1 was the only parameter that correlated with outcome (e.g., 50% survival at 1 year for patients with an FEV 1 < 1.25 L when compared to 85% survival at 1 year for patients with an FEV 1 > 1.25 L, p < 0.0001). 17 In addition, two parameters associated with response to ECP were identified in this analysis: patients with an FEV 1 rate of decline that exceeded 40 ml/month were 12 times more likely to respond to ECP and patients who had a statistically significant (p < 0.05) rate of FEV 1 decline over time (via linear regression analysis) were 10 times more likely to respond to ECP when compared to those patients whose rate of FEV 1 decline over time was not statistically significant (p > 0.05).

Under its Medicare Coverage and Evidence Development (CED) authority, CMS published a Decision Memo 18 authorising use of ECP for treatment of Medicare patients with BOS in the setting of an approved research protocol. In September 2012, CMS approved our prospective, multi-centre registry study with a target enrolment of 160 patients over 5 years to attain our primary spirometric rate of decline endpoint (50% decrease in the rate of decline in FEV 1 between a 6-month period before and after enrolment). 19 After 1 year of enrolment (n = 44), despite improvement in rate of decline in FEV1 observed in the entire cohort, a higher than expected mortality rate was also observed within the first year after enrolment. Therefore, a preliminary analysis was performed with the primary aim of assessing the factors associated with early mortality before completion of the 6-month ECP regimen. Since the protocol construct did not allow patients to receive ECP treatment unless they met defined spirometric criteria, we also wanted to compare the survival between patients who were non-randomly assigned to the either the ECP treatment versus Observation cohorts.

Subjects were enrolled in an ongoing, multicentre, study involving Medicare lung transplant recipients diagnosed with BOS that was refractory to conventional therapy, and therefore eligible to be treated with ECP. Subjects were recruited from nine centres from April 2015 to July 2016. 19 This study protocol (NCT 02181257) was initially approved by the Washington University Human Research Protection Office and subsequently by all local IRBs at enrolling centres.

All subjects enrolled in this study received prophylactic standard immunosuppressive therapy pursuant to local practices at enrolling institutions. Pulmonary function was monitored by serial spirometry following lung transplant in accordance with guidelines issued by the American Thoracic Society (ATS). 20 BOS diagnoses were rendered using clinical criteria predicated by FEV 1 values as defined by the International Society for Heart and Lung Transplantation. 21 Enrolling sites had full discretion to administer any new therapy and/or augment the current immunosuppressive regimen after diagnosis of BOS. Refractory BOS was defined as a progressive decline in FEV 1 unresponsive to all interventions as determined by the enrolling investigator.

Enrolled subjects were initially assigned to one of two (ECP vs. Observation) cohort on a non-randomised basis predicated on the spirometric criteria previously described 17 ; subjects who met the spirometric criteria (i.e., a statistically significant rate of FEV 1 decline that exceeded 10 ml/month if the most recent pre-ECP FEV 1 was <1200 or 30 ml/month if FEV1 > 1200 ml) were assigned to the ECP Treatment cohort. Subjects who were enrolled in the study but who did not initially meet these spirometric criteria were assigned to the Observation cohort. For subjects in the Observation cohort who continued to have FEV 1 values regularly monitored after enrolment, ECP treatment could be initiated when the subject's FEV1 values subsequently met the aforementioned spirometric criteria; these Observation cohort subjects were designated post hoc as a "Crossover."

Subjects that met the enrolment spirometric rate of decline criteria either initially (ECP Treatment cohort) or with Crossover (Observation cohort) were scheduled to receive 24 ECP treatments over a period of 6 months, using a regimen previously described. 9 In summary, treatment centres performed ECP using the intravenous formulation of 8 methoxy psolarin (UVADEX™) with either the UVAR XTS or CELLEX instruments (Therakos, Exton, PA) predicated on instrument availability, patient-specific indications or operator experience. 

To assess the relative efficacy of ECP to arrest the rate of decline in lung function, the rate of decline in FEV 1 was calculated via linear regression using five FEV 1 values obtained 6 months prior to enrolment, and using at least four FEV1 values obtained at 6 and 12 months after ECP initiation predicated on availability of FEV 1 values 2 months after the first ECP procedure. Only patients who had at least three monthly FEV 1 values after the first ECP treatment were included in the comparative analysis. The change in rate of decline between the pre and post-ECP periods was calculated as the difference between the slope of FEV 1 decline post-ECP (e.g., 3, 6 or 12 months) and the rate of decline just prior to ECP initiation (slope post-ECP À slope pre-ECP ).

The primary endpoint of the Registry study was the change in rate of FEV 1 decline with "response" defined as a 50% or greater decrease in the rate of FEV 1 decline between pre-ECP and 6 months post-ECP treatment.

2.6 | Secondary outcomes 2.6.1 | Relationship between initial rate of FEV1 decline and response to ECP To assess the ability of our spirometric enrolment criteria to identify subjects who respond to ECP, "response" at 3 or 6 months after ECP was summarised for ECP and Observation Crossover Cohort subjects; predictive indices with respect to the ability of spirometric enrolment criteria to identify response were derived using Bayes' Theorem.

As part of our DSMB safety assessment functions, mortality was adjudicated with respect to relatedness to ECP by our DSMB while causality was assessed by local managing physicians. Time to mortality was determined for all subjects who expired within 12 months of enrolment and early mortality was defined as death prior to completion of the 6-month ECP regimen (i.e., 24 ECP procedures). The following factors were assessed with respect to a potential association with early mortality: demographics, indication, and type of transplant, the rate and degree of decline of pulmonary function at enrolment. In addition, response to ECP and study design-related factors (i.e., spirometric enrolment criteria) were also evaluated.

To characterise the impact of the requisite time for BOS on the magnitude of decline in FEV 1 at enrolment, % change from baseline FEV 1 values were summarised at various times point in a subset (n = 18) of patients who were initially assigned to ECP treatment whose BOS diagnosis was made within 6 months prior to enrolment.

Chi square and Fischer's exact test were used to compare orical variables. Either two-sample Wilcoxon rank-sum or one-way analysis of variance was used for comparison of continuous variables at one or more time periods. In circumstances where there were missing data (in part related to early mortality), specific data points were displayed in distribution plots rather than mean values and when data were expressed as mean values in tables, the number of data points for each condition was included.

Univariate linear regression was used to evaluate the decline in lung function via generation of slope values using time (independent variable) and FEV 1 values (dependent variable) at multiple different time periods.

Univariate and multivariate linear regression analyses were performed to identify potential covariates that may be associated with mortality at either 6 or 12 months after enrolment and with response to ECP therapy; only variables that had a p value <0.1 with univariate analyses were included in multivariate models. A p value of <0.05 was considered statistically significant. Statistical analyses were performed using STATA14 software (StataCorp, College Station, TX).

Of 44 patients enrolled in the ECP Registry Study, 31 were initially assigned to the ECP cohort while 13 were assigned to the Observation cohort in a non-randomised fashion based on spirometric enrolment criteria. Thirty-seven subjects received ECP as follows: 30 of 31 ECP Treatment cohort patients received ECP (one excluded due to venous access issues) while 6 of 7 observation cohort subjects who crossed over received ECP therapy (Crossover Cohort) (see Figure 1 ). The average number of days between enrolment and the first ECP treatment was 10 days for ECP cohort subjects while Crossover subjects received ECP on average 28 days after observation cohort enrolment; this 18 day difference translated into an average loss of 51 ml in FEV 1 .

Demographic, primary disease indication for transplant, type of lung transplant (i.e., single vs. bilateral), and stage of BOS at enrolment were similar between the two cohorts (Table 1) . A substantial percentage of patients were in advanced stages (58% vs. 50% in Stage II/III in the ECP and Observation cohorts, respectively).

A similar overall distribution of maintenance immunosuppressive medications was observed between cohorts (Table 2) . Accordingly, similar percentages of patients had received either Azithromycin or anti-thymocyte globulin between the two cohorts, with p values of 0.3 and 1.0, respectively ( Table 2 ). Table 3 summarises FEV 1 values at four time points in each cohort (ECP vs. observation vs. crossover). When compared to the ECP cohort, the screening FEV 1 was statistically lower (p < 0.01) in the observation subjects who did not cross-over to ECP treatment. Table 4 summarises rates of FEV 1 decline and p values (i.e., values derived from the FEV 1 versus time plots and slopes expressed in ml/month) between cohorts at two time points (before and 6 months after enrolment); the number of data points included was predicated on availability of FEV 1 measurements as detailed at the bottom of the table. As expected based on the spirometric criteria for cohort F I G U R E 1 A flow diagram that illustrates patient enrolment on a non-random basis using spirometric enrolment criteria, assignment and crossover to extracorporeal photopheresis (ECP) treatment assignment, the slopes of FEV1 decline pre-enrolment were much steeper (p = 0.004) in the ECP cohort (À192 ± 167 ml/month) when compared to the observation cohort (À46 ± 46 ml/month).

3.4.1 | Primary outcome: Assessment of spirometric "response"

The primary outcome of the registry study with respect to the change in the rate of FEV1 decline could only be assessed in a subset of enrolled patients that had at least six monthly FEV1 values after ECP treatment as follows: 63% (19 of 30) of ECP cohort subjects and 71% (5 of 7) Crossover subjects. At 6 months, 19 evaluable ECP cohort subjects demonstrated a 93% decrease (from À136 to À10 ml/month, p = 0.0002) in the mean rate of FEV1 decline after ECP (Table 4, Figure 2 ). In contrast, only a trend (p = 0.29) in reduced mean rate of FEV1 decline (65%) 6 months after ECP was observed in 5 initially assigned Observation patients who crossed over to ECP treatment ( crossover Observation cohort subjects, no patient (0%) had a change in their FEV1 rate of decline as they continued to have a stable FEV 1 pattern for at least 3 months after enrolment (i.e., no change in FEV1 rate of declinesee Figure E4 for all non-Crossover subjects). Figure 3 ). description of the etiology of mortality between cohorts at various time periods is summarised in Table 5 . The most common primary cause of death among all non-survivors (both ECP cohort and Observation cohort subjects) was respiratory or graft failure (90%). There was no difference in mortality between the two cohorts (p = 0.2).

Although a higher numeric percentage of subjects initially assigned to ECP treatment (n = 31) expired at both 6 (ECP: 39% vs. Obs: 23%) and 12 (ECP: 48% vs. Obs: 31%) months after enrolment when compared to subjects initially assigned to Observation (n = 13), these trends were not significant p = 0.49 and p = 0.34, respectively. These findings were not unexpected as they were most likely related to subject assignment in a non-random fashion using spirometry-based criteria which assigned subjects to ECP treatment based on higher rates of FEV1 decline.

To evaluate the potential effects of reduced lung function on survival, (Table S1, Figure E1 ). However, similar mean FEV 1 values were observed at baseline and at enrolment between Survivors and non-survivors (Table S1 ). These findings were explained by the comparison of rate of decline in FEV 1 between survival cohorts. Significantly (p = 0.009) higher rates of FEV 1 decline were observed in the non-survivors (À232 ± 195 ml/month) when compared to the survivors (À101 ± 110 ml/ month) at 6 months and similarly at 12 months after enrolment (p = 0.002) (Table S1 ). When all relevant covariates were included in a multivariate logistic regression analysis to identify potential variables associated with either early mortality or 12 month mortality, only preenrolment FEV 1 rate of decline in lung function was associated with both early (6 month) (p = 0.005) and 12 month mortality (p = 0.005). T A B L E 5 Mortality after enrolment between non-randomised cohorts allocated to either ECP treatment or observation based on spirometric criteria 

Although ECP was associated with a 93% reduction in the rate of decline in FEV 1 at 6 months after ECP initiation in our non-randomised registry study, we also observed a concerning early mortality rate.

Safety of the ECP procedure was assessed by our DSMB which adjudicated that none of the fatal outcomes were related to ECP and local investigators characterised that 92% were due to end-stage pulmonary dysfunction. Although higher than expected mortality was observed after enrolment in patients non-randomly assigned to ECP Treatment based on spirometry criteria, these findings were related to the more aggressive nature of BOS in patients assigned to ECP treatment (i.e., statistically significant fourfold greater rate of FEV1 decline in patients assigned to ECP treatment) which was shown to be the most important and only factor associated with mortality; this artefact was clearly related to the study design since spirometric criteria were used to assign patients to treatment in a non-randomised fashion with those assigned to ECP having a resultant much greater rate of FEV1 decline.

With respect to our study design, our current analysis revealed that our spirometric criteria enabled accurate identification of responders to ECP. In the Observation cohort involving patients with low rates of sis. 17 We also confirmed that the current spirometric enrolment criteria can detect patients who respond to ECP and should not have a substantial clinical impact with respect to delay in ECP treatment since the time for crossover was nominal (18 days) with minimal loss of FEV 1 volume in that period.

The findings of low FEV 1 values at BOS diagnosis ( Figure 4 ) and the higher rates of decline in FEV 1 in non-survivors highlights the potential importance of early detection and expedited management of BOS with ECP as first line therapy rather than use for refractory disease to arrest disease progression before lung function reaches a critically low level. Accordingly, we have modified our CMS approved study to now include a randomised controlled trial (RCT) arm that involves use of ECP as first line therapy when compared to local standard of care management of BOS.

Delays in detection of BOS may also be an important factor that led to higher early mortality in our series. In summary, these preliminary analyses support earlier detection and treatment of BOS especially in patients who have a rapid decline in lung function. In light of the preliminary suggestion of ECP's efficacy in reducing the rate of decline of lung function, we are modifying our study to add an RCT arm that will enrol patients with newly diagnosed BOS. Based on these findings, we will continue to utilise our spirometric criteria to enrol patients who are more likely to respond to ECP. 

Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the pulmonary council of the ISHLT

The registry of the International Society for Heart and Lung Transplantation: thirtysecond official adult lung and heart-lung transplantation report-2015; focus theme: early graft failure

Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure

Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors

Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients

Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis

Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors

Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study

Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis transplantation study Group

Photopheresis for chronic rejection of lung allografts

Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation

Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis

Extracorporeal photopheresis for the treatment of lung allograft rejection

Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience

A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation

The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation

Factors associated with mortality and response to extracorporeal photopheresis in lung allograft recipients with bronchiolitis obliterans syndrome

Standardisation of spirometry

An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians

Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities?

Improving survival outcomes in lung transplant recipients through early detection of bronchiolitis obliterans: daily home spirometry versus standard pulmonary function testing

Daily home spirometry facilitates early detection of rejection in single lung transplant recipients with emphysema

Effect of adherence to home spirometry on bronchiolitis obliterans and graft survival after lung transplantation

Decision support for the triage of lung transplant recipients on the basis of home-monitoring spirometry and symptom reporting

New telemetric system for daily pulmonary function surveillance of lung transplant recipients

SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article. How to cite this article: The EPI Study Group